Adults with endometrial cancer invited to be in a research study testing the addition of the immunotherapy drug to the usual chemotherapy treatment

UVA Tracking #
Principal Investigator
Linda R Duska
Sheena Clift
Contact Phone
Official Trial Title
A Phase II Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have endometrial cancer. The purpose of this study is to find out if we can lower the chance of your endometrial cancer growing or spreading by adding a new immunotherapy drug, pembrolizumab, to the usual combination of chemotherapy drugs, paclitaxel and carboplatin.

Everyone in the study will get either paclitaxel and carboplatin with pembrolizumab or paclitaxel and carboplatin with a placebo for four and a half months, followed by only pembrolizumab or only a placebo for up to two years. Placebo looks like the study drug but contains no medication. Neither you nor your doctor(s) will know which treatment you are receiving--this is called a blinded study.

After you finish your study treatment, your doctor and study team will continue to follow your condition every 3 months for 2 years after treatment. After that, they will check you every 6 months for 3 years. This means you will keep seeing your doctor for up to 5 years after treatment.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here: